VRTX $181.97 +1.47 (0.81%)
Vertex Pharmaceuticals Inc
Vertex Stock Charts
The 5 year and 1 year stock charts are below.
50 Day Moving Average
The 50 Day Moving Average is at $157.66 which is 15.42% below the stock price of $181.97.
200 Day Moving Average
The 200 Day Moving Average is at 156.30 which is 16.42% below the stock price of $181.97.
Because both the 50 DMA and 200 DMA are below the current stock price, this can be considered a bullish technical indicator.
Since the stock price is very far from both moving averages, a price retracement towards the moving averages should not be unexpected.
VRTX Stock Price
Below are a few key dates for the stock price.
Year To Date
The most recent stock price is $181.97.
The Year To Date (YTD) return is +19.00%.
52 Week Low
The 52 Week Low stock price is $127.67 set on Tue, Jul 18, 2017 which is 363 days ago.
The current price per share is 42.53% above the 52 week low.
52 Week High
The 52 Week High stock price is $182.16 set on Mon, Jul 16, 2018 which is Today. View all of today's 52 week highs.
The current price per share is -0.10% below the 52 week high.
All Time High
The All Time High stock price is $182.16 set on Mon, Jul 16, 2018 which is Today.
The current price per share is -0.10% below the all time high.
Below is the EPS, P/E Ratio and Earnings Date.
The Earnings Per Share (EPS) is $0.88.
The Price To Earnings (P/E) Ratio is 204.19.
Vertex has a relatively high price to earnings ratio compared to the overal S&P 500 average, which is about 25%.
Some investors look for very low p/e stocks with the hopes of investing in an undervalued stock. Of course, this is just one factor to consider.
Stocks can make big percentage moves on the earnings announcement.
Companies announce earnings either before the market open or after the close.
The Earnings Release Date for Vertex Pharmaceuticals Inc was Wed, Jan 31, 2018.
Since this earnings release 166 days ago, the stock price is up by +9.27%.
Many investors know the importance of a companies earnings report. Also, the market reaction to the earnings release can be even more important and can help in making a prediction of a future price forecast of the shares.
A significant post earnings announcement percentage move can continue or reverse an existing trend for several days or weeks after the earnings date.
The most recent Earnings Release Date was on Thu, Apr 26, 2018, which was 81 days ago.
Since this earnings date, the stock price is up by +17.29%.
Below is important Dividend information.
VRTX currently does not pay a dividend.
You may like this list of best dividend stocks of 2018.
Biotech & Pharma Industry
Below are other stocks in the same industry as Vertex.
VRTX Company Profile
Learn more about Vertex.
Vertex Pharmaceuticals Inc is a Health Care stock that trades on the NASDAQ and has a market capitalization of $45.43 Billion.
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
Spend a few minutes browsing the Vertex Pharmaceuticals Inc, web site at http://www.vpharm.com.